Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 May 15;123(20):3073-9.
doi: 10.1182/blood-2014-01-550020. Epub 2014 Mar 19.

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

Joaquin Martinez-Lopez  1 , Juan J Lahuerta  1 , François Pepin  2 , Marcos González  3 , Santiago Barrio  1 , Rosa Ayala  1 , Noemí Puig  3 , María A Montalban  1 , Bruno Paiva  4 , Li Weng  2 , Cristina Jiménez  3 , María Sopena  1 , Martin Moorhead  2 , Teresa Cedena  1 , Immaculada Rapado  1 , María Victoria Mateos  3 , Laura Rosiñol  5 , Albert Oriol  6 , María J Blanchard  7 , Rafael Martínez  8 , Joan Bladé  5 , Jesús San Miguel  4 , Malek Faham  2 , Ramón García-Sanz  3
Affiliations
Clinical Trial

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

Joaquin Martinez-Lopez et al. Blood. .

Abstract

We assessed the prognostic value of minimal residual disease (MRD) detection in multiple myeloma (MM) patients using a sequencing-based platform in bone marrow samples from 133 MM patients in at least very good partial response (VGPR) after front-line therapy. Deep sequencing was carried out in patients in whom a high-frequency myeloma clone was identified and MRD was assessed using the IGH-VDJH, IGH-DJH, and IGK assays. The results were contrasted with those of multiparametric flow cytometry (MFC) and allele-specific oligonucleotide polymerase chain reaction (ASO-PCR). The applicability of deep sequencing was 91%. Concordance between sequencing and MFC and ASO-PCR was 83% and 85%, respectively. Patients who were MRD(-) by sequencing had a significantly longer time to tumor progression (TTP) (median 80 vs 31 months; P < .0001) and overall survival (median not reached vs 81 months; P = .02), compared with patients who were MRD(+). When stratifying patients by different levels of MRD, the respective TTP medians were: MRD ≥10(-3) 27 months, MRD 10(-3) to 10(-5) 48 months, and MRD <10(-5) 80 months (P = .003 to .0001). Ninety-two percent of VGPR patients were MRD(+). In complete response patients, the TTP remained significantly longer for MRD(-) compared with MRD(+) patients (131 vs 35 months; P = .0009).

PubMed Disclaimer

Figures

Figure 1
Figure 1
TTP and OS of series according to minimal MRD levels. (A) TTP and (B) OS for MRD levels ≤10−5 vs >10−5, as determined by deep sequencing.
Figure 2
Figure 2
TTP and OS of series stratified according to different MRD levels >10−3 vs 10−3 to 10−5 vs <10−5. (A) TTP and (B) OS, as determined by deep sequencing.
Figure 3
Figure 3
Time to progression for patients achieving conventional complete remission (CR), according to minimal residual disease (MRD) status as determined by deep sequencing.
See this image and copyright information in PMC

Comment in

  • Down to the bitter end.
    Lonial S, Gleason C. Lonial S, et al. Blood. 2014 May 15;123(20):3061-2. doi: 10.1182/blood-2014-04-565317. Blood. 2014. PMID: 24832937

References

    1. Corso A, Nozza A, Lazzarino M, et al. Plateau phase in multiple myeloma: an end-point of conventional-dose chemotherapy. Haematologica. 1999;84(4):336–341. - PubMed
    1. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists’ Collaborative Group. J Clin Oncol. 1998;16(12):3832–3842. - PubMed
    1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–2520. - PMC - PubMed
    1. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986;67(5):1298–1301. - PubMed
    1. Bladé J, Samson D, Reece D, et al. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102(5):1115–1123. - PubMed

Publication types